The impact of randomization on the analysis of clinical trials

被引:17
|
作者
Rosenkranz, Gerd K. [1 ]
机构
[1] Novartis Pharma AG, Basel, Switzerland
关键词
dynamic randomization; nonrandom sample; forced allocation; TREATMENT ALLOCATION PROCEDURES; BIASED COIN DESIGN; PROGNOSTIC-FACTORS;
D O I
10.1002/sim.4376
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The design of a comparative clinical trial involves a method of allocating treatments to patients. Usually, this assignment is performed to achieve several objectives: to minimize selection and accidental bias, to achieve balanced treatment assignment in order to maximize the power of the comparison, and most importantly, to obtain the basis for a valid statistical inference. In this paper, we are concerned exclusively with the last point. In our investigation, we will assume that measurements can be decomposed in a patient-specific effect, a treatment effect, and a measurement error. If the patient can be considered to be randomly drawn from a population, the randomization method does not affect the analysis. In fact, under this so-called population model, randomization would be unnecessary to obtain a valid inference. However, when individuals cannot be considered randomly selected, the patient effects may become fixed but unknown constants. In this case, randomization is necessary to obtain valid statistical analyses, and it cannot be precluded that the randomization method has an impact on the results. This paper elaborates that the impact can be substantial even for a two-sample comparison when a standard t-test is used for data analysis. We provide some theoretical results as well as simulations. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:3475 / 3487
页数:13
相关论文
共 50 条
  • [21] RANDOMIZATION IN CLINICAL-TRIALS - REPLY
    STAMM, WE
    COUNTS, GW
    MCKEVITT, M
    ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) : 790 - 790
  • [22] Randomized exposure-controlled trials;: impact of randomization and analysis strategies
    Karlsson, Kristin E.
    Grahnen, Anders
    Karlsson, Mats O.
    Jonsson, E. Niclas
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) : 266 - 277
  • [23] APPLYING RESULTS OF RANDOMIZED TRIALS TO CLINICAL-PRACTICE - IMPACT OF LOSSES BEFORE RANDOMIZATION
    CHARLSON, ME
    HORWITZ, RI
    BRITISH MEDICAL JOURNAL, 1984, 289 (6454): : 1281 - 1284
  • [24] INFORMED CONSENT IN CLINICAL-TRIALS AND ITS IMPACT ON METHODS OF RANDOMIZATION AND STATISTICAL EVALUATION
    HILDENBRAND, G
    BAUR, MP
    HILDENBRAND, K
    ONKOLOGIE, 1979, 2 (06): : 221 - 225
  • [25] PROPERTIES OF THE URN RANDOMIZATION IN CLINICAL-TRIALS
    WEI, LJ
    LACHIN, JM
    CONTROLLED CLINICAL TRIALS, 1988, 9 (04): : 345 - 364
  • [26] Bayesian doubly adaptive randomization in clinical trials
    XIAO YiKe
    LIU ZhongQiang
    HU FeiFang
    Science China(Mathematics), 2017, 60 (12) : 2503 - 2514
  • [27] RANDOMIZATION DESIGNS IN COMPARATIVE CLINICAL-TRIALS
    ELLENBERG, SS
    NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21): : 1404 - 1408
  • [28] STATISTICAL PROPERTIES OF RANDOMIZATION IN CLINICAL-TRIALS
    LACHIN, JM
    CONTROLLED CLINICAL TRIALS, 1988, 9 (04): : 289 - 311
  • [29] Randomization tests for multiarmed randomized clinical trials
    Wang, Yanying
    Rosenberger, William F.
    Uschner, Diane
    STATISTICS IN MEDICINE, 2020, 39 (04) : 494 - 509
  • [30] RESTRICTED RANDOMIZATION DESIGNS IN CLINICAL-TRIALS
    SIMON, R
    BIOMETRICS, 1979, 35 (02) : 503 - 512